Correlation Between APOBEC3B Expression and Clinical Characterization in Lower-Grade Gliomas

Area of Science:

• Oncology
• Genomics
• Immunology

Background:

• Gliomas are aggressive central nervous system tumors with limited treatment options.
• Immunotherapy offers a promising avenue for glioma treatment.
• APOBEC3B, a genomic mutation inducer, is explored for its role in gliomas.

Purpose of the Study:

• To investigate the expression pattern of APOBEC3B in gliomas.
• To assess APOBEC3B's value as an immune biomarker and immunotherapeutic target.
• To explore the correlation between APOBEC3B and tumor mutations and clinical characteristics.

Main Methods:

• Analysis of transcriptional data from TCGA and CGGA datasets.
• Investigation of the association between APOBEC3B and clinical features, prognosis, and immune infiltration.
• Immunohistochemistry staining on samples from the Xiangya cohort.

Main Results:

• APOBEC3B expression is higher in advanced gliomas and correlates with poorer prognosis.
• APOBEC3B levels stratified patient survival in the Xiangya cohort.
• APOBEC3B is associated with immune cell infiltration, tumor mutation, and oncogenic gene regulation.

Conclusions:

• APOBEC3B is a potential molecular target for glioma treatment.
• APOBEC3B may serve as a prognostic and predictive biomarker in gliomas.